MAPT and early-onset autosomal dominant Alzheimer disease: Aβ is thought to lead to the emergence or enrichment of other pathologies, such as hyperphosphorylated tau, as the disease progresses.5,7,8 Thus, targeting Aβ accumulation in the preclinical stage of Alzheimer’s disease may be an effective strategy for preventing cognitive decline.5,7,9